Healthcap

Market position

HealthCap positions itself as a leading European venture capital firm investing exclusively in life sciences, comparing its output to that of a large pharmaceutical company: it states that portfolio companies have produced more than 30 market-approved pharmaceutical products, corresponding to almost five percent of all FDA approvals over the relevant period, plus 50 approved innovative medical devices. Site figures cite 136 portfolio companies financed, 35 approved pharmaceutical products, 48 IPOs across fourteen markets and more than five million patients treated.

HealthCap emphasises in-house medical and scientific depth — a team spanning medicine, biochemistry, drug development, clinical practice, investment banking and finance, with a majority of staff at partner level — combined with hands-on board-level ownership and company creation rather than purely passive financing. It also emphasises a long operating history since 1996 and an explicit ESG framework, including signatory status to the Principles for Responsible Investment and alignment with UN Sustainable Development Goals 3 and 9.

Technology

HealthCap does not develop technology itself; its exposure is to portfolio company platforms including antibody-drug conjugates, targeted radiopharmaceuticals, gene and cell therapies, vaccines, peptide and small-molecule therapeutics, MRI-based body composition informatics, digital health applications and implantable and interventional medical devices.

Go-to-market

The firm sources opportunities through its scientific and industrial networks and academic relationships, and in some cases creates companies itself. After investing, one or more partners take board seats and the firm uses its networks to recruit experienced executives and directors to portfolio companies, applying what it describes as a transparent corporate governance model and active ownership through to exit.

On the investment side, HealthCap targets start-ups and emerging life science companies developing therapeutics and medical devices for diseases with high unmet medical need, including rare diseases, cancers and genetic diseases, at stages spanning company creation through to pre-IPO. On the capital-raising side, its counterparties are institutional investors such as pension funds, insurers, development finance institutions, foundations and university endowments.

Geography

Headquartered in Stockholm, Sweden, with a second office in Lausanne, Switzerland. Investment activity is European-anchored but global, with portfolio companies across the Nordics, continental Europe, the United Kingdom, Ireland, North America and Canada. Portfolio company IPOs have taken place on fourteen different markets.

History

Established in 1996 in Stockholm with its first fund, HealthCap raised successive vehicles over the following decades, including a fourth biotech fund reported to have closed at $322 million in 2001 and HealthCap VIII, established in 2019. As of 2023 the firm reported eight funds, roughly 25 employees of whom thirteen were partners, and committed capital exceeding EUR 1 billion; its own site later reports nine funds raised since 1996. Notable portfolio outcomes over the firm's history include Actelion (Swiss Stock Exchange listing in 2000, acquired by Johnson & Johnson), Q-Med (acquired by Galderma in 2011), CoreValve (acquired by Medtronic), Algeta (Oslo listing in 2007, acquired by Bayer in 2014), Aerocrine (Nasdaq OMX Stockholm listing in 2007, acquired by Circassia Pharmaceuticals in 2015), Aerogen (acquired by Nektar in 2005) and Wilson Therapeutics (acquired by Alexion in 2018).

Risks & controversies

Public figures for portfolio scale differ between sources — the firm's site cites 136 companies financed, 35 approved pharmaceutical products and 48 IPOs, while its About page cites 131, 34 and 47 and an encyclopaedia entry cites over 125 companies, eight funds and more than 20 pharmaceutical products — so headline metrics should be treated as approximate and date-dependent. As a life science investor, the firm notes that drug development and manufacturing are heavily regulated, requiring Good Clinical Practice compliance, agency authorisation and ethics committee approval, and that ESG risk identification is embedded in due diligence.